Kymera Therapeutics (KYMR) announced that it will host a video webcast on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics announces first patient dosed in BROADEN Phase 1b trial
- Kymera Therapeutics appoints Goodman as Chief Business Officer
- Cautious Hold Rating on Kymera Therapeutics Amid Promising KT-621 Prospects and Strategic Developments
- Kymera Therapeutics initiated with a Buy at Citi
- Kymera Therapeutics: Leading the Way with Innovative STAT6 Degrader KT-621